Literature DB >> 9025759

Implementation and evaluation of patient-specific three-dimensional internal dosimetry.

K S Kolbert1, G Sgouros, A M Scott, J E Bronstein, R A Malane, J Zhang, H Kalaigian, S McNamara, L Schwartz, S M Larson.   

Abstract

UNLABELLED: Current methods for calculating the absorbed dose in a target region from a source region rely on a standard "reference man" geometry and assume an uniform distribution of radiolabel. While this approach is acceptable at the low levels of radioisotope administered for most diagnostic purposes, the generality of the calculations is not adequate for doses at the higher levels required for therapy and is not easily extendible to tumor dosimetry.
METHODS: We have developed an integrated system which utilizes patient anatomy and radionuclide distribution in the calculation of absorbed dose rate or total dose to any user-defined target region. Images of radionuclide distribution (PET/SPECT) are registered to anatomic images (CT/ MRI) and then entered into a three-dimensional internal dosimetry software system (3D-ID) where regions of interest are defined. Dose calculations are performed by the mathematical convolution between a user-specified, dose-point kernel with the activity in the source volume over the target volume. The resulting dose rate distribution may be scaled by cumulated activity to yield absorbed dose. In addition to calculating the mean dose, dose-volume histograms may be generated which plot absorbed dose with respect to percent of volume. The method was evaluated using selected standard man phantom organs.
RESULTS: Dose estimates for two patient studies are included to illustrate differences between patient-specific and MIRD-based calculations. The package provides an alternative approach to image display and three-dimensional internal dose calculations.
CONCLUSION: The dose-volume histogram representation of absorbed dose to a target volume provides valuable information in assessing tumor control probability and normal tissue toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9025759

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  Assessment of MIRD data for internal dosimetry using the GATE Monte Carlo code.

Authors:  Ali Asghar Parach; Hossein Rajabi; Mohammad Ali Askari
Journal:  Radiat Environ Biophys       Date:  2011-05-15       Impact factor: 1.925

Review 2.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

3.  Metabolic Tumor Volume in Lymphoma: Hype or Hope?

Authors:  Heiko Schöder; Craig Moskowitz
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

4.  VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4.

Authors:  Susan D Kost; Yuni K Dewaraja; Richard G Abramson; Michael G Stabin
Journal:  Cancer Biother Radiopharm       Date:  2015-01-16       Impact factor: 3.099

5.  Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.

Authors:  Hong Song; Bin He; Andrew Prideaux; Yong Du; Eric Frey; Wayne Kasecamp; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2006-12       Impact factor: 10.057

6.  Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.

Authors:  Jianting Yue; Thibault Mauxion; Diane K Reyes; Martin A Lodge; Robert F Hobbs; Xing Rong; Yinfeng Dong; Joseph M Herman; Richard L Wahl; Jean-François H Geschwind; Eric C Frey
Journal:  Med Phys       Date:  2016-10       Impact factor: 4.071

Review 7.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

8.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

9.  Adsorption of metallic radionuclides on plastic phantom walls.

Authors:  Mi-Ae Park; Ashfaq Mahmood; Robert E Zimmerman; Naengnoi Limpa-Amara; G Mike Makrigiorgos; Stephen C Moore
Journal:  Med Phys       Date:  2008-04       Impact factor: 4.071

10.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.